BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...$1.8 million) since 2018 in a program from the lab of Stuart Forbes at the University of Edinburgh...
BioCentury | Jun 22, 2020
Finance

In a first for the British Business Bank, firm backs Epidarex’s new fund

...in the fund, contributing £50 million, with the remainder coming from LPs such as the University of Edinburgh...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

...pharma moved its live biotherapeutic therapy closer to the clinic, and Cyclacel partnered with the University of Edinburgh...
...Amid COVID-19 Crisis” ). Cyclacel, Edinburgh’s CDK inhibitors Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) partnered with the University of Edinburgh...
...protein TLR4 - Toll-like receptor 4 Elizabeth S. Eaton, Staff Writer Ultomiris, ravulizumab-cwvz (ALXN1210) CYC065 Alexion Pharmaceuticals Inc. Cyclacel Pharmaceuticals Inc. University of Edinburgh Zydus...
BioCentury | Dec 12, 2019
Tools & Techniques

New hepatic stellate cell subset drives liver fibrosis

...A team including University of Edinburgh and Gilead researchers has used single-cell sequencing to zero in on a...
...receptor 1 RXRA (RXRα) - Retinoid X receptor alpha SOX4 - SRY-box 4 Hongjiang Li, Staff Writer University of Edinburgh Gilead...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...tiered royalties 2019 Imperial College London ; Oxford Biomedica plc (LSE:OXB); University of Oxford ; University of Edinburgh...
BioCentury | Jun 5, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

...YTHDF2) Patient sample, cell culture and mouse studies suggest inhibiting YTHDF2 could help treat AML University of Edinburgh...
BioCentury | May 29, 2019
Preclinical News

May 29 Preclinical Quick Takes: Vor debuts lead stem cell program; plus an inverse Alzheimer's-cancer target, and statins for cognitive defects

...for the target between Alzheimer's and cancer. Lovastatin corrects Fragile X syndrome cognitive defects A University of Edinburgh...
...SORL1 (gp250; LR11) - Sortilin-related receptor 1 Mary Romeo, Staff Writer Columbia University Massachusetts Institute of Technology PureTech Health plc University of Edinburgh University...
BioCentury | May 14, 2019
Distillery Therapeutics

Inhibiting YTHDF2 to treat AML

...University of Edinburgh, Edinburgh, U.K. email: donal.ocarroll@ed.ac.uk CONTACT: Kamil R. Kranc, same affiliation as above email: kamil.kranc@qmul.ac.uk Claire Quang University of Edinburgh YTH...
BioCentury | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

...hired Stuart Cobb as its first CSO. Cobb is also a principal investigator at the University of Edinburgh...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...online Oct. 4, 2018 doi:10.1016/j.chembiol.2018.09.005 CONTACT: E. Elizabeth Patton, University of Edinburgh, Edinburgh, U.K. email: e.patton@igmm.ed.ac.uk Jaime De Leon University of Edinburgh Aldehyde...
Items per page:
1 - 10 of 138
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...$1.8 million) since 2018 in a program from the lab of Stuart Forbes at the University of Edinburgh...
BioCentury | Jun 22, 2020
Finance

In a first for the British Business Bank, firm backs Epidarex’s new fund

...in the fund, contributing £50 million, with the remainder coming from LPs such as the University of Edinburgh...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

...pharma moved its live biotherapeutic therapy closer to the clinic, and Cyclacel partnered with the University of Edinburgh...
...Amid COVID-19 Crisis” ). Cyclacel, Edinburgh’s CDK inhibitors Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) partnered with the University of Edinburgh...
...protein TLR4 - Toll-like receptor 4 Elizabeth S. Eaton, Staff Writer Ultomiris, ravulizumab-cwvz (ALXN1210) CYC065 Alexion Pharmaceuticals Inc. Cyclacel Pharmaceuticals Inc. University of Edinburgh Zydus...
BioCentury | Dec 12, 2019
Tools & Techniques

New hepatic stellate cell subset drives liver fibrosis

...A team including University of Edinburgh and Gilead researchers has used single-cell sequencing to zero in on a...
...receptor 1 RXRA (RXRα) - Retinoid X receptor alpha SOX4 - SRY-box 4 Hongjiang Li, Staff Writer University of Edinburgh Gilead...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...tiered royalties 2019 Imperial College London ; Oxford Biomedica plc (LSE:OXB); University of Oxford ; University of Edinburgh...
BioCentury | Jun 5, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

...YTHDF2) Patient sample, cell culture and mouse studies suggest inhibiting YTHDF2 could help treat AML University of Edinburgh...
BioCentury | May 29, 2019
Preclinical News

May 29 Preclinical Quick Takes: Vor debuts lead stem cell program; plus an inverse Alzheimer's-cancer target, and statins for cognitive defects

...for the target between Alzheimer's and cancer. Lovastatin corrects Fragile X syndrome cognitive defects A University of Edinburgh...
...SORL1 (gp250; LR11) - Sortilin-related receptor 1 Mary Romeo, Staff Writer Columbia University Massachusetts Institute of Technology PureTech Health plc University of Edinburgh University...
BioCentury | May 14, 2019
Distillery Therapeutics

Inhibiting YTHDF2 to treat AML

...University of Edinburgh, Edinburgh, U.K. email: donal.ocarroll@ed.ac.uk CONTACT: Kamil R. Kranc, same affiliation as above email: kamil.kranc@qmul.ac.uk Claire Quang University of Edinburgh YTH...
BioCentury | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

...hired Stuart Cobb as its first CSO. Cobb is also a principal investigator at the University of Edinburgh...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...online Oct. 4, 2018 doi:10.1016/j.chembiol.2018.09.005 CONTACT: E. Elizabeth Patton, University of Edinburgh, Edinburgh, U.K. email: e.patton@igmm.ed.ac.uk Jaime De Leon University of Edinburgh Aldehyde...
Items per page:
1 - 10 of 138